Tag Archives | companion diagnostics

Rayno DX and Tools Mid Year Review and AACC Update: ABAX, ILMN, HOLX, TMO.. Update-2

Update -2 Aug. 1 Draft Guidance on LDTs Coming from FDA in 60 Days: Tests Must Be Validated More regulation coming means greater development costs and potential time delays for clinical tests in development and currently marketed as LDTs . Presumably LDT tests will be allowed to remain on the market. Potential intermediate term impact […]

Continue Reading

Rayno Life Sciences: First Half Stock Performance Part 2-ILMN, SQNM

Rayno Diagnostics and Tools-Sequencing Rules Diagnostics and Tools stocks tracked biotech stocks during the huge moves in January/February and sold off until the April bottom. However stocks that are more revenue and earnings driven -Cardiovascular Systems(CSII) and Quidel (QDEL)- did not recover to former highs. Sequenom  (SQNM) is a leader in non-invasive pre-natal tests such […]

Continue Reading

Rayno Diagnostics and Tools Stocks: GHDX, ILMN, QGEN, RGDX.

Rayno Life Science Stocks Focused on Genetic Tests and Biomarkers We have been writing about molecular diagnostics and tools stocks for over 5 years. Here is the summary of our Portfolio. Yesterday we provided an update from BIO 2014  on personalized medicine and genetic tests. Many genetic tests are not FDA approved usually called LDTs […]

Continue Reading

Clinical Tools and Diagnostic Companies:Financial Metrics 2014 Q1Results

Clinical Diagnostic Stocks Were Hit By Bio-Bubble or Revenue Miss Potential upside in EXAS, NSTG and NEOG all are Rayno Dx and Tools picks. With “momentum trading” days over for now, revenue growth is the focus. Companies with disappointing Q1 revenues: Abaxis (ABAX), Alere (ALR), Response Genetics (RGDX) and Quidel (QDEL). Q2 recovery will be key. […]

Continue Reading

Rayno Dx and Tools 2014 YTD After OCT. Correction: ABAX EXAS ILMN

Update 11/24/14   Clinical Diagnostics and Tools Stocks Review Performance YTD and compared to 11/13 YTD Top winners YTD are: EXAS 104%, ILMN 71.4%, ABAX 36.8% Top Losers YTD are: NSTG 16.6%, RGDX 54%, VRML 30.9% but all were good trades. IWM at $117.4 See Performance Data Below ———————-Previous post——— April Sell-Off Hit Diagnostic Small […]

Continue Reading